Purple Biotech Ltd.: Purple Biotech Reports Second Quarter 2026 Financial Results
Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2026 results and new preclinical data on its IM1240 tri-specific antibody. The company said IM1240 showed an 8-fold longer half-life and 16-fold higher exposure versus a non-capped variant, with reduced cytokines in toxicology work. Cash was $6.1 million at June 30, 2026, funding a runway to mid-2027. IM1240 is planned for clinical entry in 2027.
How this was made
The 30-second read
Why it matters
The article combines (1) Q2 2026 financials and liquidity runway and (2) new EACR 2026 preclinical data intended to de-risk the mechanism and safety profile for IM1240’s planned first-in-human study.
Market read
Traders get a fresh catalyst set: updated liquidity runway through mid-2027 plus conference-backed preclinical differentiation for IM1240, which can move micro-cap biotech sentiment and expectations for partnering/financing.
What to watch
The PR emphasizes non-GLP toxicology and patient-derived ex vivo data, but does not provide dosing, planned Phase 1 endpoints, or partner/financing terms that could materially change near-term capital needs.
Background
Purple Biotech is a clinical-stage immunotherapy company developing the CAPTN-3 masked tri-specific antibody platform; IM1240 is targeted for clinical entry in 2027.
Ticker impact
Purple Biotech reported Q2 2026 results and new EACR preclinical data supporting IM1240’s safety, PK, and therapeutic window, plus a mid-2027 cash runway.
Near-term upside bias on biotech sentiment around IM1240 differentiation, tempered by dilution/financing overhang into mid-2027.
This is a primary company PR with concrete preclinical datapoints and a stated cash runway, but it is not yet a clinical readout or a funding event.
Market effects
Adds incremental validation for next-gen T-cell engager designs using masking/capping and NKG2A engagement, relevant to competitive positioning in oncology immunotherapy.
Limited, company-specific impact; no broader regional policy or funding signal disclosed.
Modest, as it is a single clinical-stage biotech update without cross-sector regulatory or macro catalysts.
Counterpoint
Preclinical differentiation may not translate into first-in-human tolerability or efficacy; the cash runway statement highlights potential dilution risk before Phase 1 milestones.
Key entities
- companyPurple Biotech Ltd.
Clinical-stage immunotherapy developer reporting Q2 2026 financial results and new IM1240 preclinical data.
- product_candidateIM1240
Tri-specific antibody (capped-CD3x5T4xNKG2A) with reported improved half-life, exposure, and reduced cytokine release versus a non-capped variant.
- technology_platformCAPTN-3 platform
Masked tri-specific antibody platform designed to confine immune activation to the tumor microenvironment.
- eventEACR 2026 Annual Congress
Conference where the company presented the new preclinical IM1240 data.
